natgillin/translations-raw huggingface dataset:
Baseline liver function tests should be undertaken in all patients and treatment should not be initiated in patients with baseline values of ALT and/or AST &gt; 3 X upper limit of normal (see section 4.3).
Kod svih bolesnika prije početka liječenja potrebno je napraviti testove funkcije jetre i liječenje se ne smije započeti u bolesnika kod kojih su vrijednosti ALT-a i/ili AST-a &gt; 3 puta gornja granica normale na početku liječenja (vidjeti dio 4.3).
Baseline values of hepatic aminotransferases (aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT) &gt; 3 × ULN) (see sections 4.2 and 4.4).
Početne vrijednosti jetrenih aminotransferaza (aspartat-aminotransferaza (AST) i/ili alanin- aminotransferaza (ALT) &gt; 3 × GGN); (vidjeti dijelove 4.2 i 4.4).
Baseline values of hepatic aminotransferases (aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT)) &gt; 3xULN (see sections 4.2 and 4.4).
Početna vrijednost jetrenih aminotransferaza (aspartat aminotransferaze (AST) i/ili alanin aminotransferaze (ALT)) &gt; 3 x GGN (vidjeti dijelove 4.2 i 4.4).
Baseline-adjusted initial PK parameters of VWF and FVIII:C in subjects &lt; 6 (N=9) and 6-12 years old (N=5)
Inicijalni PK parametri VWF i FVIII:C među ispitanicima &lt; 6 (N=9) i 6-12 godina (N=5)
BATCH NUMBER, &lt; DONATION AND PRODUCT CODES &gt;
BROJ SERIJE, &lt; OZNAKE DONACIJE I PROIZVODA &gt;
BATCH NUMBER &lt; , DONATION AND PRODUCT CODES &gt;
BROJ SERIJE &lt; , OZNAKE DONACIJE I PROIZVODA &gt;
BATCH NUMBER &lt; , DONATION AND PRODUCT CODES &gt;
BROJ SERIJE, OZNAKA DONACIJE I PROIZVODA
BATCH NUMBER &lt; , DONATION AND PRODUCT CODES &gt;
BROJ SERIJE, OZNAKE DONACIJE I PROIZVODA
BATCH NUMBER &lt; , DONATION AND PRODUCT CODES &gt;
BROJ SERIJE &lt; , DONACIJA I ŠIFRE PROIZVODA &gt;
Batch {number}
&lt; Serija &gt; &lt; Lot &gt; {broj}
Batch {number}
Lot &gt; {broj}
Bausch &amp; Lomb-IOM S.p.A. Tel: + 39 (0)2 27407300
Bausch &amp; Lomb-IOM S.p.A. Tel: + 39 (0) 2 27407300
Bazedoxifene has not been studied in women with triglyceride levels 300 mg/dl (3.4 mmol/litre).
Bazedoksifen nije ispitivan u žena čije su razine triglicerida &gt; 300 mg/dl ( &gt; 3,4 mmol/l).
Before the third dose of Eurartesim, in one of the two Phase III studies 3/767 patients (0.4%) were reported to have a QTcF value of &gt; 500 ms versus none in the comparator group.
Prije treće doze Eurartesima, u jednom od dva ispitivanja faze III, zabilježeno je da je 3/767 bolesnika (0,4%) imalo vrijednost QTcF &gt; 500 ms naspram nijednog bolesnika u usporednoj skupini.
Belatacept has not been studied in patients with Panel Reactive Antibody (PRA) &gt; 30% (who often require increased immunosuppression).
Belatacept se nije ispitivao u bolesnika s panelom reaktivnih protutijela (PRA, Panel Reactive Antibody) većim od 30% (kojima je često potrebna pojačana imunosupresija).
Belatacept has not been studied in patients with PRA &gt; 30% (see section 4.2).
Belatacept se nije ispitivao u bolesnika u kojih je PRA &gt; 30% (vidjeti dio 4.2).
Betmiga has not been studied in patients with end stage renal disease (GFR &lt; 15 mL/min/1.73 m2 or patients requiring haemodialysis) or severe hepatic impairment (Child-Pugh Class C) and it is therefore not recommended for use in these patient populations (see sections 4.4 and 5.2).
Betmiga nije ispitivan u bolesnika u terminalnom stadiju bubrežne bolesti (GFR &lt; 15 ml/min/1,73 m2 ili bolesnicima koji su zahtijevali hemodijalizu) ili s teškim oštećenjem jetre (Child-Pugh stadij C) te se stoga ne preporučuje njegova primjena u tim populacijama bolesnika (vidjeti dio 4.4 i 5.2).
Between weeks 6 and 26, symptoms of psoriasis gradually returned with a median time to disease relapse of &gt; 20 weeks.
Između 6. i 26. tjedna simptomi psorijaze postupno su se vratili, uz medijan od &gt; 20 tjedana do povratka bolesti.
BIAL-Portela &amp; Cª, S.A. Tel.: + 351 22 986 61 00 (Portugália)
Tel: + 43 (0) 1 535 1980-0
BIAL-Portela &amp; Cª, S.A. Tel: + 351 22 986 61 00 (Portugal)
BIAL - Portela &amp; Cª , S.A tel: +351 22 986 61 00
BIAL-Portela &amp; Cª, S.A. Tel: + 351 22 986 61 00 (Portugal)
BIAL - Portela &amp; Cª , S.A tel: +351 22 986 61 00 (Portugal)
BIAL-Portela &amp; Cª, S.A. Tel: + 351 22 986 61 00 (Portugalia)
BIAL-Portela &amp; Cª, S.A. Tel: + 351 22 986 61 00 (Portugal) (Portugalia)
BIAL-Portela &amp; Cª., S.A. Tel.: + 351 22 986 61 00
BIAL-Portela &amp; Cª, S.A. Tel.: + 351 22 986 61 00 (Portugália)
Bilirubin &lt; ULN and normal AST
Bilirubin &lt; GGN i normalan AST
Bilirubin &lt; ULN and raised AST
Bilirubin &lt; GGN i povišeni AST
Bilirubin &lt; 1.25 X upper normal limit
Bilirubin &lt; 1,25 puta gornja normalna granica
Bilirubin &gt; ULN but &lt; 50 μmol/l
Bilirubin &gt; GGN ali &lt; 50 μmol/l
Binding studies using traditional neuropathological staining methods in post-mortem AD brains demonstrated statistically significant (p &lt; 0.0001) correlations between in vitro florbetapir (18F) binding and β-amyloid aggregate deposition.
Ispitivanja vezivanja primjenom tradicionalnih metoda neuropatološkog bojanja mozgova oboljelih od Alzheimerove bolesti post mortem pokazala su statistički značajne (p &lt; 0,0001) korelacije između vezivanja florbetapira (18F) in vitro i stvaranja nakupina β-amiloida.
Biochemical adverse drug reactions include alanine aminotransferase increased (24%), hyperbilirubinaemia (16%), aspartate aminotransferase increased (12%), lipase increased (11%), blood bilirubin increased (10%), hyperglycaemia (4%), hypercholesterolaemia (3%) and hypertriglyceridaemia ( &lt; 1%).
Biokemijske nuspojave na lijek uključuju povišenje alanin aminotransferaze (24%), hiperbilirubinemiju (16%), povišenje aspartat aminotransferaze (12%), povišenje lipaze (11%), povišenje bilirubina u krvi (10%), hiperglikemiju (4%), hiperkolesterolemiju (3%) i hipertigliceridemiju ( &lt; 1%).
Blast crisis and Ph+
trombociti &lt; 50 x 109/l
Bleeding events associated to thrombocytopenia occurred in &lt; 1% of patients treated with the monotherapy regimen.
Krvarenja povezana s trombocitopenijom pojavila su se u &lt; 1 % bolesnika liječenih režimom monoterapije.
Blood and lymphatic system disorders: Thrombocytopenia (In the pooled phase III trials, these events were uncommon (≥ 1/1,000 to &lt; 1/100)).
Poremećaji krvi i limfnog sustava: trombocitopenija (u objedinjenim ispitivanjima faze III, ti su događaji bili manje česti (≥ 1/1,000 i &lt; 1/100)).
Blood glucose decreased ( &lt; 55 mg/dl) 
Snižena razina glukoze u krvi ( &lt; 55 mg/dl)
Blood glucose decreased ( &lt; 55 mg/dl) 
Snižena razina glukoze u krvi ( &lt; 55 mg/dl) x
Blood glucose decreased ( &lt; 55 mg/dl) 
Snižena razina glukoze u krvi ( &lt; 55 mg/dl) 
Blood urea nitrogen &lt; 1.5x upper normal limit
Urea nitrat u krvi &lt; 1 puta gornja normalna granica
Blood urea nitrogen &lt; 1.5 X upper normal limit
Urea nitrat u krvi &lt; 1,5 puta gornja normalna granica
Body weight &lt; 60 kg
Tjelesna težina &lt; 60 kg
Body weight &gt; 40 kg
Tjelesna težina &gt; 40 kg
Body weight was reduced by 0.4 kg with an estimated treatment difference between Xultophy and insulin degludec of -2.80 kg (p &lt; 0.0001), and the rate of confirmed hypoglycaemia remained 1.8 events per patient year of exposure maintaining a significant reduction in overall risk of confirmed hypoglycaemia compared to insulin degludec.
Tjelesna težina smanjila se za 0,4 kg, uz procijenjenu razliku u liječenju između lijeka Xultophy i degludek inzulina od -2,80 kg (p &lt; 0,0001), a stopa potvrđene hipoglikemije ostala je 1,8 događaja po bolesnik-godini izloženosti, čime je održano značajno smanjenje ukupnog rizika od potvrđene hipoglikemije u usporedbi s degludek inzulinom.
Boehringer Ingelheim Pharma GmbH &amp; Co. KG Binger Strasse 173
Boehringer Ingelheim Pharma gmbH &amp; Co.KG Binger Strasse 173
Boehringer Ingelheim Pharma GmbH &amp; Co. KG Birkendorfer Strasse 65
Boehringer Ingelheim Pharma GmbH &amp; Co.KG Birkendorfer Strasse 65
Boehringer Ingelheim Pharma GmbH &amp; Co. KG D-55216 Ingelheim am Rhein
Boehringer Ingelheim Pharma GmbH &amp; Co.KG D-55216 Ingelheim am Rhein
Boehringer Ingelheim RCV GmbH &amp; Co
Boehringer Ingelheim RCV GmbH &amp; Co KG
Boehringer Ingelheim RCV GmbH &amp; Co
Boehringer Ingelheim RCV GmbH &amp; Co KG Magyarországi Fióktelepe
Boehringer Ingelheim RCV GmbH &amp; Co KG
Boehringer Ingelheim RCV GmbH &amp; Co KG Animal Health
Boehringer Ingelheim RCV GmbH &amp; Co KG Eesti Filiaal
Boehringer Ingelheim RCV GmbH &amp; CoKG Eesti Filiaal
Boehringer Ingelheim RCV GmbH &amp; Co KG Latvijas filiāle
Boehringer Ingelheim Pharma GmbH Pārstāvniecība Latvijā
Boehringer Ingelheim RCV GmbH &amp; Co KG organizačná zložka
Boehringer Ingelheim RCV GmbH &amp; Co KG, organizačná zložka
Boehringer Ingelheim RCV GmbH &amp; Co KG Podružnica Ljubljana
Boehringer Ingelheim RCV GmbH &amp; Co KG, podružnica Ljubljana
Boehringer Ingelheim RCV GmbH &amp; Co KG Tel: +43 1 80 105-0
Boehringer Ingelheim RCV GmbH &amp; Co KG Tel: +43 1 80 1050
Boehringer Ingelheim RCV GmbH &amp; Co KG Viena - Sucursala Bucuresti
Boehringer Ingelheim RCV GmbH &amp; Co KG Viena Sucursala Bucuresti
Boehringer Ingelheim RCV GmbH &amp; Co KG, Podružnica Ljubljana
Boehringer Ingelheim RCV GmbH &amp; Co KG Podružnica Ljubljana
Boehringer Ingelheim RCV GmbH &amp; Co Tel: +353 1 295 9620 Podružnica Ljubljana
Boehringer Ingelheim RCV GmbH &amp; Co KG Tel: +353 1 295 9620 Podružnica Ljubljana
Boehringer Ingelheim RCV GmbH &amp; Co Tel: +385 1 2444 600 Viena - Sucursala Bucuresti
Boehringer Ingelheim RCV GmbH &amp; Co KG Tel: +385 1 2444 600 Viena - Sucursala Bucuresti
Boehringer-Ingelheim RCV GmbH &amp; Co KG, Dr.-Boehringer-Gasse 5-11, 1121 Vienna, Austria Name and address of the manufacturer responsible for batch release
Boehringer-Ingelheim RCV GmbH &amp; Co KG, Dr.-Boehringer-Gasse 5-11, 1121 Beč, Austrija Naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet
Bone marrow depression1 including neutropenia ( &lt; 2.0 x 109/l), reticulocytopenia ( &lt; 80 x 109/l), macrocytosis2
depresija koštane srži1 uključujući neutropeniju ( &lt; 2,0 x 109/l), retikulocitopeniju ( &lt; 80 x 109/l), makrocitozu2
Bortezomib Hospira therapy should be withheld when the platelet count is &lt; 25,000/μl or, in the case of combination with melphalan and prednisone, when the platelet count is ≤ 30,000/μl (see section 4.2).
Liječenje lijekom Bortezomib Hospira mora se uskratiti kad je broj trombocita &lt; 25 000/µl, a u slučaju kombinacije s melfalanom i prednizonom kad je broj trombocita ≤ 30 000/µl (vidjeti dio 4.2).
Bortezomib therapy should be withheld when the platelet count is &lt; 25,000/μl or in combination with melphalan and prednisone when the platelet count is ≤ 30,000/μl (see section 4.2).
Liječenje bortezomibom mora se prekinuti kad je broj trombocita &lt; 25 000/μl, a u slučaju kombinacije s melfalanom i prednizonom kad je broj trombocita ≤ 30 000/μl (vidjeti dio 4.2).
Bortezomib therapy should be withheld when the platelet count is &lt; 25,000/l or, in the case of combination with melphalan and prednisone, when the platelet count is ≤ 30,000/l (see section 4.2).
Liječenje bortezomibom mora se prekinuti kad je broj trombocita &lt; 25 000/l, a u slučaju kombinacije s melfalanom i prednizonom kad je broj trombocita ≤ 30 000/l (vidjeti dio 4.2).
Bosentan is highly bound ( &gt; 98%) to plasma proteins, mainly albumin.
Bosentan je u velikom postotku vezan ( &gt; 98%) za proteine plazme, uglavnom albumin.
Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p &lt; 0.05).
U 16. tjednu primjene 25 mg alogliptina, samog i u kombinaciji s 30 mg pioglitazona, postiže se u usporedbi s placebom značajno smanjenje postprandijalne glukoze i postprandijalnog glukagona uz značajni porast postprandijalnih razina aktivnog GLP-1 (p &lt; 0,05).
Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p &lt; 0.05).
U 16. tjednu primjene 25 mg alogliptina, samog i u kombinaciji s 30 mg pioglitazona, postižu se u odnosu na placebo značajna smanjenja postprandijalne glukoze i postprandijalnog glukagona uz značajno povećanje postprandijalnih razina aktivnog GLP-1 (p &lt; 0,05).
Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p &lt; 0.05).
U 16. tjednu primjene 25 mg alogliptina, samog i u kombinaciji s 30 mg pioglitazona, postižu se, u odnosu na placebo, značajna smanjenja postprandijalne glukoze i postprandijalnog glukagona uz značajni porast postprandijalnih razina aktivnog GLP-1 (p &lt; 0,05).
Both phase 3 studiesexcluded patients with uncontrolled hypertension, clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or NYHA Class III or IV heart failure (study 301) or Class II to IV heart failure (study 302) or cardiac ejection fraction measurement of &lt; 50%.
Ni u jedno od dva ispitivanja faze III nisu uključivani bolesnici s nekontroliranom hipertenzijom, klinički značajnom bolešću srca koja se manifestirala infarktom miokarda ili arterijskim trombotičkim događajima u prethodnih 6 mjeseci, bolesnici s teškom ili nestabilnom anginom te bolesnici sa zatajivanjem srca NYHA stupnja III i IV (ispitivanje 301) ili zatajenjem srca stupnja II do IV (ispitivanje 302) ili ejekcijskom frakcijom srca &lt; 50%.
Both piperaquine and artenimol are highly bound to human plasma proteins: the protein binding observed in in vitro studies was 44-93% for artenimol and &gt; 99% for piperaquine.
I piperakin i artenimol u visokom su postotku vezani za proteine ljudske plazme: vezanje za proteine opaženo u ispitivanjima in vitro iznosilo je 44-93% za artenimol i &gt; 99% za piperakin.
Both treatment groups showed statistically and clinically significant mean decreases from baseline in worse eye IOP at all follow up timepoints throughout the study (p &lt; 0.001).
U obje ispitivane skupine zabilježen je statistički i klinički značajan srednje pad vrijednost intraokularnog tlaka u odnosu na polazne vrijednosti u lošijem oku u svim vremenskim točkama mjerenja tijekom ispitivanja (p &lt; 0,001).
BOTTLE LABEL 5 ml &amp; 10 ml
NALJEPNICA NA BOČICI 5 ml i 10 ml
Bradycardia &lt; 50 beats per minute (bpm)
Bradikardija &lt; 50 otkucaja u minuti
Bravecto 112.5 mg (2–4.5 kg) Bravecto 250 mg ( &gt; 4.5 –10 kg) Bravecto 500 mg ( &gt; 10 –20 kg) Bravecto 1000 mg ( &gt; 20 –40 kg) Bravecto 1400 mg ( &gt; 40 –56 kg)
Bravecto 112,5 mg (2-4,5 kg) Bravecto 250 mg ( &gt; 4,5 -10 kg) Bravecto 500 mg ( &gt; 10-20 kg) Bravecto 1000 mg ( &gt; 20-40 kg) Bravecto 1400 mg ( &gt; 40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs ( &gt; 4.5 –10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs ( &gt; 10 –20 kg) Bravecto 1000 mg chewable tablets for large dogs ( &gt; 20 –40 kg) Bravecto 1400 mg chewable tablets for very large dogs ( &gt; 40–56 kg)
Bravecto 112,5 mg tablete za žvakanje za vrlo male pse (2-4,5 kg) Bravecto 250 mg tablete za žvakanje za male pse ( &gt; 4,5 -10 kg) Bravecto 500 mg tablete za žvakanje za srednje velike pse ( &gt; 10-20 kg) Bravecto 1000 mg tablete za žvakanje za velike pse ( &gt; 20-40 kg) Bravecto 1400 mg tablete za žvakanje za vrlo velike pse ( &gt; 40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs ( &gt; 4.5 –10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs ( &gt; 10–20 kg) Bravecto 1000 mg chewable tablets for large dogs ( &gt; 20–40 kg) Bravecto 1400 mg chewable tablets for very large dogs ( &gt; 40–56 kg)
Bravecto 112,5 mg tablete za žvakanje za vrlo male pse (2-4,5 kg) Bravecto 250 mg tablete za žvakanje za male pse ( &gt; 4,5-10 kg) Bravecto 500 mg tablete za žvakanje za srednje velike pse ( &gt; 10-20 kg) Bravecto 1000 mg tablete za žvakanje za velike pse ( &gt; 20-40 kg) Bravecto 1400 mg tablete za žvakanje za vrlo velike pse ( &gt; 40-56 kg)
Bravecto 112.5 mg chewable tablets for very small dogs (2–4.5 kg) Bravecto 250 mg chewable tablets for small dogs ( &gt; 4.5–10 kg) Bravecto 500 mg chewable tablets for medium-sized dogs ( &gt; 10–20 kg) Bravecto 1000 mg chewable tablets for large dogs ( &gt; 20–40 kg) Bravecto 1400 mg chewable tablets for very large dogs ( &gt; 40–56 kg)
Bravecto 112,5 mg tablete za žvakanje za vrlo male pse (2-4,5 kg) Bravecto 250 mg tablete za žvakanje za male pse ( &gt; 4,5 -10 kg) Bravecto 500 mg tablete za žvakanje za srednje velike pse ( &gt; 10-20 kg) Bravecto 1000 mg tablete za žvakanje za velike pse ( &gt; 20-40 kg) Bravecto 1400 mg tablete za žvakanje za vrlo velike pse ( &gt; 40-56 kg)
Bravecto 112.5 mg spot-on solution for very small dogs (2 – 4.5 kg) Bravecto 250 mg spot-on solution for small dogs ( &gt; 4.5 – 10 kg) Bravecto 500 mg spot-on solution for medium-sized dogs ( &gt; 10 – 20 kg) Bravecto 1000 mg spot-on solution for large dogs ( &gt; 20 – 40 kg) Bravecto 1400 mg spot-on solution for very large dogs ( &gt; 40 – 56 kg)
Bravecto 112,5 mg otopina za nakapavanje za vrlo male pse (2 - 4,5 kg) Bravecto 250 mg otopina za nakapavanje za male pse ( &gt; 4,5 - 10 kg) Bravecto 500 mg otopina za nakapavanje za srednje velike pse ( &gt; 10 - 20 kg) Bravecto 1000 mg otopina za nakapavanje za velike pse ( &gt; 20 - 40 kg) Bravecto 1400 mg otopina za nakapavanje za vrlo velike pse ( &gt; 40 - 56 kg)
Bravecto 112.5 mg spot-on solution for very small dogs (2 – 4.5 kg) Bravecto 250 mg spot-on solution for small dogs ( &gt; 4.5 – 10 kg) Bravecto 500 mg spot-on solution for medium-sized dogs ( &gt; 10 – 20 kg) Bravecto 1000 mg spot-on solution for large dogs ( &gt; 20 – 40 kg) Bravecto 1400 mg spot-on solution for very large dogs ( &gt; 40 – 56 kg) fluralaner
Bravecto 112,5 mg otopina za nakapavanje za vrlo male pse (2 - 4,5 kg) Bravecto 250 mg otopina za nakapavanje za male pse ( &gt; 4,5 - 10 kg) Bravecto 500 mg otopina za nakapavanje za srednje velike pse ( &gt; 10 - 20 kg) Bravecto 1000 mg otopina za nakapavanje za velike pse ( &gt; 20 - 40 kg) Bravecto 1400 mg otopina za nakapavanje za vrlo velike pse ( &gt; 40 - 56 kg) fluralaner
Bravecto 112.5 mg spot-on solution for very small dogs (2-4.5 kg) Bravecto 250 mg spot-on solution for small dogs ( &gt; 4.5 – 10 kg) Bravecto 500 mg spot-on solution for medium-sized dogs ( &gt; 10 - 20 kg) Bravecto 1000 mg spot-on solution for large dogs ( &gt; 20 – 40 kg) Bravecto 1400 mg spot-on solution for very large dogs ( &gt; 40 – 56 kg) fluralaner
Bravecto 112,5 mg otopina za nakapavanje za vrlo male pse (2 - 4,5 kg) Bravecto 250 mg otopina za nakapavanje za za male pse ( &gt; 4,5 - 10 kg) Bravecto 500 mg otopina za nakapavanje za srednje velike pse ( &gt; 10 - 20 kg) Bravecto 1000 mg otopina za nakapavanje za velike pse ( &gt; 20 - 40 kg) Bravecto 1400 mg otopina za nakapavanje za vrlo velike pse ( &gt; 40 - 56 kg)
Brimica Genuair demonstrated a rapid onset of action within 5 minutes of the first inhalation relative to placebo (p &lt; 0.0001).
Brimica Genuair pokazao je brzi nastup djelovanja unutar 5 minuta od prve inhalacije u odnosu na placebo (p &lt; 0,0001).
Brinzolamide and N-desethyl-brinzolamide are the predominant components found in the urine along with trace levels ( &lt; 1%) of the N-desmethoxypropyl and O-desmethyl metabolites.
Predominantne komponente u urinu su brinzolamid i N-dezetil-brinzolamid, zajedno s N-dezmetoksipropilnim i O-dezmetilnim metabolitima koji se nalaze u tragovima ( &lt; 1%).
Brinzolamide and N-desethylbrinzolamide are the predominant components in the urine along with trace levels ( &lt; 1%) of the N-desmethoxypropyl and O-desmethyl metabolites.
Brinzolamid i N-desetil-brinzolamid su predominantne sastavnice u urinu, zajedno s N- dezmetoksipropilnim i O-dezmetilnim metabolitima u tragovima ( &lt; 1%).
BROADLINE spot-on solution for cats &lt; 2.5 kg BROADLINE spot-on solution for cats 2.5-7.5 kg
BROADLINE otopina za nakapavanje za mačke &lt; 2,5 kg BROADLINE otopina za nakapavanje za mačke 2,5-7,5 kg
BROADLINE spot-on solution for cats &lt; 2.5 kg BROADLINE spot-on solution for cats 2.5–7.5 kg
BROADLINE otopina za nakapavanje za mačke &lt; 2,5 kg BROADLINE otopina za nakapavanje za mačke 2,5 do 7,5 kg
BROADLINE spot-on solution for cats &lt; 2.5 kg BROADLINE spot-on solution for cats 2.5–7.5 kg
BROADLINE spot on otopina za mačke &lt; 2,5 kg BROADLINE spot on otopina za mačke 2,5 kg -7,5 kg
BROADLINE spot-on solution for cats &lt; 2.5 kg BROADLINE spot-on solution for cats 2.5–7.5 kg
BROADLINE spot-on otopina za mačke &lt; 2,5 kg BROADLINE spot-on otopina za mačke 2,5 do 7,5 kg
Bronchitol has not been studied in patients with a history of significant episodes of haemoptysis ( &gt; 60 ml) in the previous three months.
Bronchitol nije ispitan u pacijenata s anamnezom značajnih epizoda hemoptize ( &gt; 60 ml) u prethodna tri mjeseca.
By 2 years 39%; P &lt; .0001
Do 2. godine 39%; P &lt; 0,0001
By 3 years 50%; P &lt; .0001
Do 3. godine 50%; P &lt; 0,0001
By 4 years 56%; P &lt; .0001
Do 4. godine 56%; P &lt; 0,0001
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA &lt; 400 copies/ml ( &lt; 50 copies/ml) in the REYATAZ + ritonavir arm and the lopinavir + ritonavir arm were 55% (40%) and 56% (46%), respectively.
Analizom prema liječenju, isključujući vrijednosti koje su nedostajale, udio bolesnika s HIV RNK &lt; 400 kopija/ml ( &lt; 50 kopija/ml) u skupini koja je primala REYATAZ s ritonavirom iznosio je 55% (40%), a u skupini koja je primala lopinavir s ritonavirom 56% (46%).
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA &lt; 400 copies/ml ( &lt; 50 copies/ml) for REYATAZ + ritonavir were 84% (72%) and for lopinavir + ritonavir were 82% (72%).
Analizom prema liječenju, isključujući vrijednosti koje su nedostajale, udio bolesnika s HIV RNK &lt; 400 kopija/ml ( &lt; 50 kopija/ml) u skupini koja je primala REYATAZ s ritonavirom iznosio je 84% (72%), a u skupini koja je primala lopinavir s ritonavirom 82% (72%).
By comparison, vorapaxar exposure (AUC and Cmax) is estimated to be 19-21% lower in patients with a body weight of &gt; 100 kg compared to those weighing 60-100 kg.
Za usporedbu, procjenjuje se da je izloženost vorapaksaru (AUC i Cmax) 19-21% niža u bolesnika tjelesne težine &gt; 100 kg u odnosu na one čija je tjelesna težina 60-100 kg.
By Year 3 recurrent AR was similar across groups ( &lt; 3%) and subclinical AR identified on the 1 year protocol biopsy was 5% in both groups.
Do 3. su godine recidivi akutnog odbacivanja bili slični u svim skupinama ( &lt; 3%), a supkliničko akutno odbacivanje utvrđeno u 1. godini protokolnom biopsijom iznosilo je 5% u obje skupine.
c &gt; 48 hours of diarrhoea and/or &gt; 7 days of rash d If patient cannot tolerate 20 mg/day, permanent discontinuation of GIOTRIF should be considered
c &gt; 48 sati proljeva i/ili &gt; 7 dana osipa d Ako bolesnik ne može podnijeti 20 mg/dan, potrebno je razmotriti trajni prekid primjene GIOTRIFA
c p &lt; 0.01 compared with placebo d Patients with Itch NRS &gt; = 4 at baseline: placebo N = 135, Taltz 80 mg Q4W N = 293, Taltz 80 mg Q2W N = 303, Etanercept N = 306
c p &lt; 0,01 u usporedbi s placebom d Bolesnici s početnim NRS rezultatom za svrbež od ≥ 4: placebo N = 135, Taltz 80 mg svaka 4 tjedna N = 293, Taltz 80 mg svaka 2 tjedna N = 303, etanercept N = 306
c.1012 G &gt; T
c.998 A &gt; G
c.1087 C &gt; T
c.1085 C &gt; T
c.1088 G &gt; A
c.1087 C &gt; T
c.1102 G &gt; A
c.1088 G &gt; A
c.1196 G &gt; A or1197 G &gt; A
c.1196 G &gt; A ili1197 G &gt; A
c.140 G &gt; A or 141 G &gt; A
c.140 G &gt; A ili 141 G &gt; A
c.194 G &gt; C (putative splicing site )
c.194 G &gt; C (pretpostavljeno mjesto prekrajanja)
c.194 G &gt; T (putative splicing site )
c.194 G &gt; T (pretpostavljeno mjesto prekrajanja)
c.215 T &gt; G
c.218 C &gt; A
c.216 G &gt; A
c.214 A &gt; G
c.218 C &gt; A
c.227 T &gt; G